Fundraising Fox
/Companies
Sign in

Dorian Therapeutics

acquired by Altos LabsYC S18

San Francisco, US · Founded 2018 · 8 employees · 3 known investors

Find your way into Dorian Therapeutics

Sign up to see every warm intro you have to Dorian Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Dorian Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.

BiotechDeep TechHealthtechLongevityAnti-AgingTherapeuticsUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (S18)

Dorian Therapeutics was founded in 2018 by Maddalena Adorno and Benedetta di Robilant.

MAMaddalena Adorno
Maddalena AdornoCo-Founder and CEOMaddalena Adorno is a researcher with background in stem cells, oncology, and aging biology who has published in peer-reviewed journals including Nature, Science, and Cell, and holds three international patents in cancer and degenerative diseases. She founded Dorian Therapeutics, a biotechnology company developing senoblockers to target aging-related cellular mechanisms, which was later acquired by Altos Labs.
BDBenedetta di Robilant
Benedetta di RobilantFounder

Investors · 3

StartXlisted by StartXStanford · $10K – $1M

How we know: StartX's portfolio page · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Related companies · 4

SFA TherapeuticsSFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
dNovodNovo develops direct reprogramming technology to convert skin, blood, or fat cells into new stem cells, targeting age-related stem cell depletion. The company aims to address aging through cellular regeneration for consumers.
Rejuvenation Technologies Inc.Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
Eat BlueprintEat Blueprint prepares meals based on longevity-focused nutritional protocols, using organic and locally-sourced ingredients while excluding gluten and seed oils.

Companies working in the same space as Dorian Therapeutics.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$452.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$335.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure
Dorian Therapeutics, Inc.

In the news

Dorian Therapeutics Appoints Jeff George to Board of Directorsprnewswire.com · Feb 2021

Frequently asked questions

What does Dorian Therapeutics do?
Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.
Who founded Dorian Therapeutics?
Dorian Therapeutics was founded by Maddalena Adorno, Benedetta di Robilant in 2018.
Who are Dorian Therapeutics's investors?
Dorian Therapeutics's investors include Blumberg Capital, StartX, Y Combinator.
Who acquired Dorian Therapeutics?
Dorian Therapeutics was acquired by Altos Labs.
Where is Dorian Therapeutics headquartered?
Dorian Therapeutics is headquartered in San Francisco, US.